EE+ POEM Archive
No mortality benefit, increased risk of acute kidney injury with addition of beta-lactam to usual therapy for MRSA bacteremia
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Barry, Henry, et al., editors. "No Mortality Benefit, Increased Risk of Acute Kidney Injury With Addition of Beta-lactam to Usual Therapy for MRSA Bacteremia." EE+ POEM Archive, John Wiley & Sons, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/infoPOEMs/1315010/all/No_mortality_benefit__increased_risk_of_acute_kidney_injury_with_addition_of_beta_lactam_to_usual_therapy_for_MRSA_bacteremia.
No mortality benefit, increased risk of acute kidney injury with addition of beta-lactam to usual therapy for MRSA bacteremia. In: Barry HH, Ebell MHM, Shaughnessy AFA, et al, eds. EE+ POEM Archive. John Wiley & Sons; 2019. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1315010/all/No_mortality_benefit__increased_risk_of_acute_kidney_injury_with_addition_of_beta_lactam_to_usual_therapy_for_MRSA_bacteremia. Accessed September 19, 2024.
No mortality benefit, increased risk of acute kidney injury with addition of beta-lactam to usual therapy for MRSA bacteremia. (2019). In Barry, H., Ebell, M. H., Shaughnessy, A. F., & Slawson, D. C. (Eds.), EE+ POEM Archive. John Wiley & Sons. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1315010/all/No_mortality_benefit__increased_risk_of_acute_kidney_injury_with_addition_of_beta_lactam_to_usual_therapy_for_MRSA_bacteremia
No Mortality Benefit, Increased Risk of Acute Kidney Injury With Addition of Beta-lactam to Usual Therapy for MRSA Bacteremia [Internet]. In: Barry HH, Ebell MHM, Shaughnessy AFA, Slawson DCD, editors. EE+ POEM Archive. John Wiley & Sons; 2019. [cited 2024 September 19]. Available from: https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1315010/all/No_mortality_benefit__increased_risk_of_acute_kidney_injury_with_addition_of_beta_lactam_to_usual_therapy_for_MRSA_bacteremia.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - No mortality benefit, increased risk of acute kidney injury with addition of beta-lactam to usual therapy for MRSA bacteremia
ID - 1315010
ED - Barry,Henry,
ED - Ebell,Mark H,
ED - Shaughnessy,Allen F,
ED - Slawson,David C,
BT - EE+ POEM Archive
UR - https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1315010/all/No_mortality_benefit__increased_risk_of_acute_kidney_injury_with_addition_of_beta_lactam_to_usual_therapy_for_MRSA_bacteremia
PB - John Wiley & Sons
DB - Evidence Central
DP - Unbound Medicine
ER -
